CN115232221B - 具有防治肺部感染的薜荔多糖及其制备方法与应用 - Google Patents
具有防治肺部感染的薜荔多糖及其制备方法与应用 Download PDFInfo
- Publication number
- CN115232221B CN115232221B CN202210609494.8A CN202210609494A CN115232221B CN 115232221 B CN115232221 B CN 115232221B CN 202210609494 A CN202210609494 A CN 202210609494A CN 115232221 B CN115232221 B CN 115232221B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- ficus pumila
- ficus
- pumila
- lps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 132
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 131
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 131
- 240000002373 Ficus pumila Species 0.000 title claims abstract description 107
- 235000006718 Ficus pumila Nutrition 0.000 title claims abstract description 107
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 11
- 239000008103 glucose Substances 0.000 claims abstract description 10
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims abstract description 7
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 6
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 6
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 5
- 229930182830 galactose Natural products 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 229920005654 Sephadex Polymers 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 7
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 6
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 6
- 108090000174 Interleukin-10 Proteins 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000000770 proinflammatory effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 206010035664 Pneumonia Diseases 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 22
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 11
- 150000002772 monosaccharides Chemical class 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000032376 Lung infection Diseases 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 5
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000218218 Ficus <angiosperm> Species 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000218231 Moraceae Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- CVBNMWXECPZOLM-UHFFFAOYSA-N Rhamnetin Natural products COc1cc(O)c2C(=O)C(=C(Oc2c1)c3ccc(O)c(O)c3O)O CVBNMWXECPZOLM-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- -1 antitumor Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical group OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- UZIWRCBLXLKBID-UHFFFAOYSA-N dodecasodium sulfuric acid tetraborate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].OS(O)(=O)=O UZIWRCBLXLKBID-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Sustainable Development (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
本发明公开了一种具有防治肺部感染的薜荔多糖,薜荔多糖由摩尔比为:1.79:5.55:1.05:1.00:3.67:49.52:13.43:1.10的甘露糖、鼠李糖、葡萄糖醛酸、半乳糖醛酸、半乳糖、葡萄糖、阿拉伯糖和岩藻糖构成,其分子量为1.29×106Da。本发明通过大量实验筛选,优选薜荔多糖提取方法,并鉴定了薜荔多糖结构组成,药理实验研究表明,薜荔多糖能显著改善LPS诱导的小鼠肺组织病理学变化,能有效抑制LPS诱导的ALI小鼠促炎因子的释放,促进抗炎因子的释放。并且薜荔多糖还能有效抑制TNF‑α和IL‑6的表达,并能有效促进IL‑10的表达水平,显示出很好的抗肺部炎症的功效。
Description
技术领域
本发明涉及薜荔多糖用于预防和治疗肺部感染及其在制备药物方面的应用,属药学领域。
背景技术
目前对于肺部感染的治疗主要以积极控制原发病,遏制炎症反应和呼吸支持为主,尚无有效的治疗药物,肺部感染的康复主要靠患者的机体免疫康复。
薜荔(Ficus pumila Linn.)为桑科(Moraceae)榕属(Ficus)植物,别名馒头郎、凉粉果、木莲等。在我国主要分布在湖南、四川、海南和台湾等省。在海南主要产于昌江、儋州、文昌、保亭等市县。传统医学认为薜荔具有祛风,利湿,活血,解毒的功效,临床上用于风湿痹痛,泻痢,淋病,跌打损伤,痈肿疮疖的治疗。
研究表明薜荔提取物具有多种药理活性,包括抗炎、镇痛、抗菌、抗氧化、抗肿瘤、降血糖血脂、抗高催乳素血症、保肝作用。以薜荔为主成分的荔花鼻窦炎片对急、慢性鼻窦炎具有较好的疗效。但未发现薜荔治疗肺部感染的相关报道,也未见薜荔多糖预防和治疗肺部感染的相关报道。
发明内容
本发明的目的为:提供一种薜荔多糖的制备方法及其在治疗肺部感染疾病中的应用,该多糖具有显著的预防和治疗肺部感染的作用,可用于药物制备方面的应用。
本发明采用的技术方案为:
一种具有防治肺部感染的薜荔多糖,薜荔多糖由摩尔比为:1.79: 5.55: 1.05:1.00:3.67: 49.52: 13.43: 1.10的甘露糖、鼠李糖、葡萄糖醛酸、半乳糖醛酸、半乳糖、葡萄糖、阿拉伯糖和岩藻糖构成,其分子量为1.29×106 Da。
一种具有防治肺部感染的薜荔多糖的制备方法,包括以下步骤:取一定质量的薜荔,加入一定量的水提取,收集提取液,减压浓缩为稠膏状,加入乙醇,静置沉淀,取沉淀物,得到薜荔粗多糖;取薜荔粗多糖经DEAE纤维素和凝胶柱纯化,得到薜荔多糖。
作为优选方案,以上所述的具有防治肺部感染的薜荔多糖的制备方法,包括以下步骤:取一定质量的薜荔地上部分,除去果实和枝条,加入1~20倍量的水煎煮或回流提取1~3次,收集合并提取液,减压浓缩成浸膏状,浸膏加入5~10倍量的乙醇,沉淀,得到薜荔粗多糖;取薜荔粗多糖经DEAE-52纤维素柱纯化,以0-0.2M氯化钠洗脱,得薜荔粗多糖,薜荔粗多糖再经葡聚糖凝胶G-100纯化,得薜荔多糖。
作为优选方案,以上所述的具有防治肺部感染的薜荔多糖的制备方法,包括以下步骤:取一定质量的薜荔地上部分,除去果实和枝条,加入10~20倍量的水煎煮或回流提取1~3次,每次1~2小时,收集合并提取液,减压浓缩成浸膏状,浸膏加入5倍量的95%乙醇,沉淀,得到薜荔粗多糖;取薜荔粗多糖经DEAE-52纤维素柱纯化,以0.1M氯化钠洗脱,得薜荔粗多糖,薜荔粗多糖再上葡聚糖凝胶G-100纯化,用水洗脱,得薜荔多糖。
有益效果:本发明通过大量实验筛选,优选薜荔多糖提取方法,并鉴定了薜荔多糖结构组成,药理实验研究表明,薜荔多糖能显著改善LPS诱导的小鼠肺组织病理学变化,能有效抑制LPS诱导的ALI小鼠促炎因子的释放,促进抗炎因子的释放。并且薜荔多糖还能有效抑制TNF-α和IL-6的表达,并能有效促进IL-10的表达水平,显示出很好的抗肺部炎症的功效。
本发明可以将薜荔多糖与药学上可接受的载体制备成口服液、颗粒剂、丸剂、片剂、胶囊剂或凝胶剂等剂型。
附图说明
图1为薜荔多糖紫外全波长扫描图。
图2为标准多糖分子量标准曲线。
图3为多糖高效凝胶图谱。
图4为单糖标准品HPLC图。
图5为薜荔多糖的HPLC图。
图6为薜荔多糖的红外光谱图。
图7为薜荔多糖对小鼠肺组织湿/干比的影响。
图8为薜荔多糖对小鼠肺组的影响。
图9为薜荔多糖对BALF中TNF-α、IL-6、IL-10表达的影响。
图10 肺组织中MAPK p-ERK1/2/ERK1/2、p-p38/P38、NF-κB p-p65/p65蛋白的表达。
实施方式
下面结合具体实施例对本发明作进一步阐述,但这些实施例不应解释为限制本发明。
实施例
取薜荔400g,加入水3200ml,加热回流提取2次,每次1h,过滤收集滤液,合并,减压浓缩至稠膏状,加入5倍量的95%乙醇,沉淀,得到薜荔粗多糖。薜荔粗多糖经DEAE-52纤维素柱纯化,以0.1M的氯化钠洗脱,洗脱液浓缩,得薜荔多糖组分,薜荔多糖组分再经葡聚糖凝胶G-100纯化,用水洗脱得薜荔多糖。
实施例
取薜荔400g,加入水4000ml,加热回流提取2次,每次1h,过滤收集滤液,合并,减压浓缩至稠膏状,加入4倍量的95%乙醇,沉淀,得到薜荔粗多糖。薜荔粗多糖经DEAE-52纤维素柱纯化,以0.08M的氯化钠洗脱,得薜荔多糖组分,薜荔多糖组分再经葡聚糖凝胶G-100纯化,用水洗脱得薜荔多糖。
实施例
取薜荔400g,加入水4800ml,加热回流提取2次,每次1h,过滤收集滤液,合并,减压浓缩至稠膏状,加入3倍量的95%乙醇,沉淀,得到薜荔粗多糖。薜荔粗多糖经DEAE-52纤维素柱纯化,以0.12M的氯化钠洗脱,得薜荔多糖组分,薜荔多糖组分再经葡聚糖凝胶G-100纯化,用水洗脱得薜荔多糖。
实施例4薜荔多糖的结构分析
1、薜荔多糖的多糖含量分析
以葡萄糖为标准,采用苯酚-硫酸法测定薜荔多糖中多糖的含量。按照表1加入0.1mg/ml的葡萄糖标准液、蒸馏水、5%苯酚溶液及硫酸溶液。配制好的溶液摇匀后,室温放置30分钟,以1号管作为空白调零,测定在490nm 处的吸光度值。以葡萄糖浓度为横坐标(μg/mL),吸光度为纵坐标,绘制葡萄糖标准曲线(y = 14.126x-0.006,R = 0.9991)。精密称取实施例1薜荔多糖10 mg,置于100 ml容量瓶中,定容至刻度,配制成0.1 mg/ml的多糖样品溶液。取2 ml样品溶液,加入1 ml 5% 苯酚溶液,混匀,再加入5 ml硫酸溶液,室温下放置30min,测定在490nm 处的吸光度值。将得到的样品吸光度值代入葡萄糖标准曲线方程,从而计算薜荔多糖中的总糖含量。在490 nm处测定吸光度值为0.6794,代入标曲计算多糖含量为98.4%。
2、薜荔多糖中蛋白质的含量测定
精密称取实施例1薜荔多糖10 mg,置于100 ml容量瓶中,定容至刻度,配制成0.1mg/ml的多糖样品溶液。取1 ml多糖样品,加入5 ml考马斯亮蓝G-250试剂,混匀放置5min,在595 nm处测定样品吸光度值。将测得的吸光度值代入蛋白标准曲线中计算样品中所含的蛋白质含量。在595 nm处测定吸光度值为0.021,代入标准曲线方程(y=0.0077x-0.0045,R= 0.9996)计算蛋白含量为0.86%。
3、薜荔多糖中糖醛酸含量的测定
精密称取实施例1薜荔多糖10 mg,置于100 ml容量瓶中,定容至刻度,配制成0.1mg/ml的多糖样品溶液。取1 ml多糖样品,冰浴条件下加入6 ml四硼酸钠-硫酸溶液,混匀后沸水浴5 min,冷却至室温,加入100μl 间羟基联苯溶液,振荡至溶液澄清。在526 nm处测定吸光度值,代入半乳糖醛酸标曲线(y = 9.9939x + 0.0103,R = 0.998)计算糖醛酸含量。在526 nm处测定吸光度值为0.2615,代入标曲计算糖醛酸含量为25.13%。
4、薜荔多糖的紫外吸光光度法分析
称取10 mg 实施例1薜荔多糖样品,溶于10 ml 蒸馏水中配制成1.0 mg/mL 多糖溶液,以蒸馏水为空白,采用紫外-可见分光光度计在波长为200-600 nm范围内进行扫描,测定多糖样品中是否在260及280 nm处有吸收,观察多糖中蛋白和核酸的相对含量。薜荔多糖紫外光谱图如图1.
5、薜荔多糖的相对分子质量及纯度测定
采用高效凝胶渗透色谱法测定多糖样品的相对分子质量。
标准曲线的制作:称取已知相对分子质量的右旋糖酐标准品(分子量分别为13050、36800、64650、135350、300600、2000000),用蒸馏水配制成浓度为1.0 mg/ml的标准品溶液,过0.45 μl水系滤膜,根据下列色谱条件测定各个标准品溶液的保留时间。以标准品的保留时间为横坐标,分子量的对数值(lg M)为纵坐标,绘制分子量标准曲线,如图2。
称取一定量的实施例1薜荔多糖样品,加入蒸馏水配制成1.0 mg/ml的样品溶液,测定多糖样品的保留时间,将样品的保留时间代入分子量标准曲线,计算得到多糖的相对分子质量。多糖样品的保留时间为11.824,计算其分子量为1.29×106 Da。薜荔多糖为单峰,表示纯度较高,如图3。
6、薜荔多糖的单糖组成
采用1-苯基-3-甲基-5-吡唑啉酮(PMP)柱前衍生化反相高效液相色谱(HPLC)法分析纯化多糖的单糖组成。
分别称取甘露糖(Man)、核糖(Rib)、鼠李糖(Rham)、葡萄糖醛酸(GlcUA)、半乳糖醛酸(GlaUA)、半乳糖(Gla)、葡萄糖(Glc)、阿拉伯糖(Ara)、岩藻糖(Fuc)标准品,配制成1 mg/ml的单糖标准品溶液。取各单糖标准液1 ml,混合,得混合单糖标准品溶液。取100 μl混合单糖于具塞试管中,加入100 μl 0.5 mol/L的PMP-甲醇溶液和0.3 mol/L的NaOH溶液,70℃水浴反应70 min。反应完成后,待反应液冷却后加入100 μl 0.3 mol/L HCl溶液终止反应。以三氯甲烷萃取除去多余PMP,重复3次,离心取上清,过0.45 μm滤膜,上高效液相色谱(HPLC)法分析,如图4。
称取实施例1薜荔多糖10 mg置于安瓿瓶中,加入2 ml 2mol/L三氟乙酸(TFA),用酒精喷灯封口,120 ℃烘箱中水解2 h。水解液冷却后加入甲醇减压蒸干,重复三次至完全去除TFA,加500 μl蒸馏水得到完全酸水解样品。取薜荔多糖水解液100 μl,按上述衍生化步骤进行,得到样品溶液,上高效液相色谱(HPLC)法分析,如图5。结果显示,和单糖标准品相比,薜荔多糖中含有甘露糖、鼠李糖、葡萄糖醛酸、半乳糖醛酸、半乳糖、葡萄糖、阿拉伯糖、岩藻糖,其摩尔比为:1.79: 5.55: 1.05%: 1.00: 3.67: 49.52: 13.43: 1.10。
薜荔多糖的红外光谱分析
取实施例1薜荔多糖2 mg,加入200 mg KBr后用圆柱形模具压成透明薄片,并通过傅立叶变换红外光谱(FT-IR)在4000-400 cm-1下扫描和分析。
如图6,红外光谱结果看到在3395.98 cm-1处有一个宽而强的峰,代表了多糖的O-H拉伸振动,此为多糖的一个特征峰。在2950-3000cm−1处有一个C-H拉伸振动。在1633.49cm-1有CHO和C-O键的拉伸振动。在1200-1000cm-1范围内,在1104.65cm-1和988.79cm-1处的强而宽的吸收峰是由吡喃糖环的C-O拉伸振动造成。在859.1cm-1处存在一处吸收,可能是存在α-吡喃糖苷的结构,也说明薜荔多糖中存在糖醛酸的结构。
实施例5薜荔多糖治疗肺部感染的药效学试验
1.1动物分组及给药
72只雄性BALB/C小鼠(20-24g,6-8周龄),置于温度和光控室(22±2°C,12小时周期),湿度为55±5%,适应1周。
小鼠随机分6组(n=12):对照组,LPS组(10mg/kg),LPS+DEX组(5mg/kg),LPS+实施例1薜荔多糖组(50mg/kg、100mg/kg、200mg/kg)。对照组用生理盐水灌胃7d;LPS组鼠先用生理盐水灌胃7d,在最后一次灌胃后2h腹腔注射10mg/kg的脂多糖进行造模;地塞米松阳性组先用生理盐水灌胃6d,最后一天腹腔注射5mg/kg的地塞米松,2h后腹腔注射10mg/kg的脂多糖;薜荔多糖治疗组(50mg/kg、100mg/kg、200mg/kg)先用多糖灌胃7d,最后一次给药后2h腹腔注射10mg/kg的脂多糖。腹腔注射脂多糖12h后,收集肺组织和肺部灌洗液进行后续分析。
1.2湿/干比
LPS腹腔注射12h后,处死小鼠。取小鼠的右肺上叶,用生理盐水冲洗后吸水纸吸干表面水分,称重为湿重。然后在85℃条件下烘干48h以上后,称取干重。用湿重除以干重即得湿干比。
为了评估肺水肿的程度,本发明测定了肺组织湿/干比,结果如图7(Con-正常组;mod-模型组;DEX-地塞米松组;L-薜荔多糖低剂量组;M-薜荔多糖中剂量组;H-薜荔多糖高剂量组)所示。LPS组的湿/干比高于对照组(P<0.01)。与LPS组相比,薜荔多糖治疗组(50、100、200 mg/kg)明显降低了湿/干比(P<0.05, P<0.01, P<0.05),其中最有效为薜荔多糖中剂量(100 mg/kg)。
1.3薜荔多糖对肺组织的影响(H&E染色)
LPS腹腔注射12h后,处死小鼠。取小鼠的右肺中叶用4%多聚甲醛固定保存,随后进行苏木精和伊红(H&E)染色,观察各组肺组织的病理变化。
为了确认薜荔多糖对脂多糖诱导的ALI小鼠是否具有保护作用,采用H&E染色,对肺组织切片进行观察研究。图8(Con-正常组;mod-模型组;DEX-地塞米松组;L-薜荔多糖低剂量组;M-薜荔多糖中剂量组;H-薜荔多糖高剂量组)所示的对照组肺泡结构完好,肺泡腔清晰可见,无明显渗出物,未见组织病理学变化。模型组肺泡间隔变小,大量炎症细胞浸润间质和肺泡间隙,毛细血管扩张、出血,也有区域肺泡融合。结果显示,薜荔多糖显著改善了LPS诱导的小鼠肺组织病理学变化,且薜荔多糖低剂量和薜荔多糖高剂量相对于LPS组炎症反应有所改善。薜荔多糖中剂量组,明显改善了LPS所诱导的炎症反应,损伤最小。
1.4薜荔多糖对BALF中炎症因子的影响
LPS腹腔注射12h后,麻醉 小鼠,分离气管,用PBS对全肺进行灌洗,收集得BALF。使用相应的ELISA试剂盒(Sangon Biotech, Shanghai, P.R.China)测定小鼠BALF中肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-10和IL-6的水平。
BALF中炎症因子表达结果如图9(Con-正常组;mod-模型组;DEX-地塞米松组;L-薜荔多糖低剂量组;M-薜荔多糖中剂量组;H-薜荔多糖高剂量组)所示,结果表明,薜荔多糖能有效抑制TNF-α和IL-6的表达,并能有效促进IL-10的表达水平。与LPS模型组相比,多糖低剂量组和中剂量组TNF-α的表达明显受到抑制(P<0.01)。IL-6在薜荔多糖低剂量和中剂量组显著降低(P<0.01),而在薜荔多糖高剂量组受到抑制(P<0.05)。IL-10的表达水平在薜荔多糖中剂量组升高(P<0.05),而在薜荔多糖高剂量组高度促进(P<0.05)。结果提示,薜荔多糖能有效抑制LPS诱导的ALI小鼠促炎因子的释放,促进抗炎因子的释放。
1.5 Western blot分析
采用免疫印迹法分析肺组织中的蛋白水平。本发明采用免疫印迹法检测了MAPK信号通路相关P38/p-P38、ERK1/2/p-ERK1/2蛋白的表达,并用p-ERK1/2/ERK1/2、p-P38/P38来表达磷酸化水平。如图10(Con-正常组;mod-模型组;DEX-地塞米松组;L-薜荔多糖低剂量组;M-薜荔多糖中剂量组;H-薜荔多糖高剂量组)结果表明,在LPS刺激后,p-ERK1/2/ERK1/2和p-p38/P38蛋白表达显著升高(P<0.01)。经薜荔多糖处理后,组织中p-ERK1/2/ERK1/2和p-p38/P38蛋白的表达显著降低(P<0.05)。
以上实施例仅为本发明的示例性实施例,不用于限制本发明,本发明的保护范围由权利要求书限定。本领域技术人员可以在本发明的实质和保护范围内,对本发明做出各种修改或等同替换,这种修改或等同替换也应视为落在本发明的保护范围内。
Claims (2)
1.薜荔多糖在制备防治肺部感染的药物中的应用,薜荔多糖由摩尔比为:1.79: 5.55:1.05: 1.00:3.67:49.52:13.43: 1.10的甘露糖、鼠李糖、葡萄糖醛酸、半乳糖醛酸、半乳糖、葡萄糖、阿拉伯糖和岩藻糖构成,其分子量为1.29×106 Da;
所述的薜荔多糖由以下方法制备得到:取一定质量的薜荔地上部分,除去果实和枝条,加入10~20倍量的水煎煮或回流提取1~3次,每次1~2小时,收集合并提取液,减压浓缩成浸膏状,浸膏加入5倍量的95%乙醇,沉淀,得到薜荔粗多糖;取薜荔粗多糖经DEAE-52纤维素柱纯化,以0.1M氯化钠水溶液洗脱,得薜荔粗多糖,薜荔粗多糖再上葡聚糖凝胶G-100纯化,用水洗脱,得薜荔多糖。
2.根据权利要求1所述的应用,将薜荔多糖与药学上可接受的载体制备成口服液、颗粒剂、丸剂、片剂或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210609494.8A CN115232221B (zh) | 2022-05-31 | 2022-05-31 | 具有防治肺部感染的薜荔多糖及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210609494.8A CN115232221B (zh) | 2022-05-31 | 2022-05-31 | 具有防治肺部感染的薜荔多糖及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115232221A CN115232221A (zh) | 2022-10-25 |
CN115232221B true CN115232221B (zh) | 2023-11-17 |
Family
ID=83667732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210609494.8A Active CN115232221B (zh) | 2022-05-31 | 2022-05-31 | 具有防治肺部感染的薜荔多糖及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115232221B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005054299A1 (fr) * | 2003-12-04 | 2005-06-16 | China Pharmaceutical University | Polysaccharide, sa preparation et son utilisation |
WO2016062020A1 (zh) * | 2014-10-22 | 2016-04-28 | 北京中安佐际生物科技有限公司 | 茯苓多糖活性组分和成分、其制备方法及用途 |
CN110498863A (zh) * | 2018-05-17 | 2019-11-26 | 复旦大学 | 薜荔叶多糖及其制备方法和在制备抗补体药物中的用途 |
CN113730431A (zh) * | 2021-08-31 | 2021-12-03 | 海南医学院 | 具有抗病毒作用的薜荔多糖及其制备方法与应用 |
-
2022
- 2022-05-31 CN CN202210609494.8A patent/CN115232221B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005054299A1 (fr) * | 2003-12-04 | 2005-06-16 | China Pharmaceutical University | Polysaccharide, sa preparation et son utilisation |
WO2016062020A1 (zh) * | 2014-10-22 | 2016-04-28 | 北京中安佐际生物科技有限公司 | 茯苓多糖活性组分和成分、其制备方法及用途 |
CN110498863A (zh) * | 2018-05-17 | 2019-11-26 | 复旦大学 | 薜荔叶多糖及其制备方法和在制备抗补体药物中的用途 |
CN113730431A (zh) * | 2021-08-31 | 2021-12-03 | 海南医学院 | 具有抗病毒作用的薜荔多糖及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115232221A (zh) | 2022-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112870236B (zh) | 一种黄蜀葵花黄酮类有效部位及其制备方法与应用 | |
CN110343185B (zh) | 一种酒制黄精多糖及其在脾虚免疫功能调节方面的用途 | |
CN103554290B (zh) | 一种肿节风酸性多糖及其制备方法、应用 | |
CN104829737A (zh) | 一种覆盆子叶粗多糖及其制备方法与应用 | |
CN115232221B (zh) | 具有防治肺部感染的薜荔多糖及其制备方法与应用 | |
CN1233378C (zh) | 一种治疗口腔咽喉疾病的中药组合物及其制备方法 | |
CN107721857B (zh) | 一种从平卧菊三七中制备高纯度绿原酸的方法 | |
CN101084979B (zh) | 一种用于癌症辅助治疗药物制剂及其制备方法 | |
CN110483657B (zh) | 一种半边莲均一多糖及其制备方法和应用 | |
CN109232756B (zh) | 一种碱蓬多糖提取物及其制备方法和应用 | |
CN108752498B (zh) | 一种具有增强免疫活性的返魂草多糖及其制备方法与应用 | |
AU686161B2 (en) | Remitting agent for nephrotic syndrome and hepatopathy symptoms | |
CN101332216B (zh) | 杏香兔耳风总酚酸提取物及其制备方法 | |
CN109234335B (zh) | 一种竹黄中富含呋喃半乳糖的多糖的制备方法 | |
CN101564418B (zh) | 一种治疗口腔溃疡的药物组合物 | |
JP3638967B2 (ja) | ネフローゼ症候群及び肝障害症状の寛解剤 | |
CN109678981A (zh) | 一种红花多糖的制备方法、产品及应用 | |
JP3161882B2 (ja) | 丹参由来多糖類、その製造法および用途 | |
JP7479538B1 (ja) | 降圧効果のあるイナゴマメ多糖類及びその製造方法並び使用 | |
CN115141288B (zh) | 知母活性多糖、知母粗多糖及制备方法和应用 | |
CN110655586B (zh) | 一种啤酒花糖聚合物及其制备方法与应用 | |
CN115558035B (zh) | 一种具有免疫调节活性的天麻多糖 | |
CN111647095B (zh) | 一种白树多糖及其制备方法和应用 | |
CN111620963B (zh) | 一种多糖及其制备方法和应用 | |
CN1103227C (zh) | 龙牙楤木叶总皂甙在抗肿瘤药物制备中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |